Assessing the burden of treatment-emergent adverse events associated with atypical antipsychotic medications

被引：0
|
作者：
Pierre-Michel Llorca
Christophe Lançon
Ann Hartry
T. Michelle Brown
Dana B. DiBenedetti
Siddhesh A. Kamat
Clément François
机构：
[1] CMP B CHU Clermont-Ferrand,
[2] Université Clermont-Auvergne,undefined
[3] Laboratoire de Santé Publique Évaluation des Systèms de Soins et Santé Perçue,undefined
[4] Université de la Méditerranée,undefined
[5] Lundbeck,undefined
[6] RTI Health Solutions,undefined
[7] Research Triangle Park,undefined
[8] Otsuka Pharmaceutical Development Corporation,undefined
来源：
BMC Psychiatry | / 17卷
关键词：
Schizophrenia; Major depressive disorder; Atypical antipsychotics; Treatment-emergent adverse events;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Antipsychotic utilization and treatment-emergent diabetes - Comparison of results with and without propensity scoring
    Yang, M
    Barner, JC
    Lawson, KA
    Rascati, KL
    Crismon, ML
    Wilson, JP
    Worchel, J
    Mascarenas, J
    [J]. VALUE IN HEALTH, 2006, 9 (03) : A39 - A39
  • [42] Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents
    McIntyre, Roger S.
    Jerrell, Jeanette M.
    [J]. ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2008, 162 (10): : 929 - 935
  • [43] Serum sodium levels and related treatment-emergent adverse events during eslicarbazepine acetate use in adults with epilepsy
    Wechsler, Robert T.
    Radtke, Rodney A.
    Smith, Michael
    Vossler, David G.
    Strome, Laura
    Trinka, Eugen
    Cheng, Ilailong
    Grinnell, Todd
    Blum, David
    Vieira, Mariana
    Moreira, Joana
    Rocha, Francisco
    [J]. EPILEPSIA, 2019, 60 (07) : 1341 - 1352
  • [44] Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia
    Liu-Seifert, Hong
    Osuntokun, Olawale O.
    Feldman, Peter D.
    [J]. COMPREHENSIVE PSYCHIATRY, 2012, 53 (01) : 107 - 115
  • [45] Treatment-Emergent Adverse Events (TEAEs) by Age for Patients with Lennox-Gastaut Syndrome (LGS) Treated with Clobazam
    Isojarvi, Jouko
    Lee, Deborah
    Buchhalter, Jeffrey
    [J]. ANNALS OF NEUROLOGY, 2013, 74 : S74 - S74
  • [46] Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: Children versus adolescents
    Safer, DJ
    Zito, JM
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2006, 16 (1-2) : 159 - 169
  • [47] Impact of Adverse Events Associated With Medications in the Treatment and Prevention of Rheumatoid Arthritis
    Costello, Ruth
    David, Trixy
    Jani, Meghna
    [J]. CLINICAL THERAPEUTICS, 2019, 41 (07) : 1376 - 1396
  • [48] ATTRITION OF METHYLNALTREXONE TREATMENT-EMERGENT ADVERSE EVENTS IN PATIENTS WITH CHRONIC NONCANCER PAIN AND OPIOID-INDUCED CONSTIPATION
    Mehta, Neel
    Slatkin, Neal E.
    Stambler, Nancy
    Israel, Robert J.
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S399 - S399
  • [49] Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis
    Oh, Jiwon
    Walker, Bryan
    Giovannoni, Gavin
    Jack, Dominic
    Dangond, Fernando
    Nolting, Axel
    Aldridge, Julie
    Lebson, Lori A.
    Leist, Thomas P.
    [J]. MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2021, 7 (03)
  • [50] Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis
    Oh, J.
    Walker, B.
    Giovannoni, G.
    Jack, D.
    Dangond, F.
    Nolting, A.
    Aldridge, J.
    Lebson, L.
    Leist, T.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 316 - 316
12345